Last checked at 21 Sep 2009 09:55
| For Immediate Release | 21 September 2009 |
ImmuPharma PLC
IMMUPHARMA TO PRESENT AT 8TH ANNUAL BIO INVESTOR FORUM
ImmuPharma PLC (LSE:IMM), the drug discovery and development group announces that Dimitri Dimitriou, Chief Executive Officer will be presenting at the 2009 BIO Investor Forum. Hosted by the Biotechnology Industry Organisation (BIO), the 8th Annual BIO Investor Forum will take place on October 28-29 at the Palace Hotel in San Francisco, California.
- Ends -
For further information please contact:
| ImmuPharma PLC: | +44 20 7152 4080 |
| Dimitri Dimitriou, Chief Executive Officer | |
| Buchanan Communications: | +44 20 7466 5000 |
| Lisa Baderoon | |
Notes to Editors
About ImmuPharma PLC
ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders.
Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009
The company also has a strong proprietary and collaborative drug development pipeline.
About The Bio Investor Forum
The 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year's BIO Investor Forum will feature more than 110 presentations by private and publicly traded companies, venture philanthropy organizations, and patient advocacy groups; as well as Therapeutic Workshops™ and Business Roundtables with distinguished clinicians, investigators, and investors. Experts hand-selected to speak at this conference will focus on current biotechnology pipeline innovation, and the latest trends in clinical strategy, capital access and creative funding techniques. The Eighth Annual BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors, and research analysts as well as business development executives from leading global pharmaceutical and mature biotechnology companies.